Viatris (VTRS) Free Cash Flow (2019 - 2026)
Viatris (VTRS) posted Free Cash Flow of $329.0 million for Q2 2026, down 5.57% on a QoQ basis from $348.4 million in Q1 2026, and up 97.24% year-over-year from $166.8 million in Q2 2025.
Analysis
Viatris (VTRS) Free Cash Flow (2019 - 2026) Analysis & Trends
Viatris has reported Free Cash Flow for 8 years, with the latest figure at $329.0 million in Q2 2026.
- On a quarterly basis, Free Cash Flow rose 97.24% year-over-year to $329.0 million in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 11.61% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, down 2.01% from the prior year.
- Free Cash Flow was $329.0 million for Q2 2026 at Viatris, down from $348.4 million in the prior quarter.
- The five-year high for Free Cash Flow was $1.1 billion in Q1 2022, with the low at $35.3 million in Q4 2022.
- Average Free Cash Flow over 5 years is $539.3 million, with a median of $528.8 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow plunged 89.16% in 2022, then soared 1041.64% in 2023.
- Over 5 years, Free Cash Flow stood at $35.3 million in 2022, then jumped by 1041.64% to $403.0 million in 2023, then declined by 15.06% to $342.3 million in 2024, then surged by 80.92% to $619.3 million in 2025, then sank by 46.88% to $329.0 million in 2026.
- The last three Free Cash Flow figures came in at $329.0 million (Q2 2026), $348.4 million (Q1 2026), and $619.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 307.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 329.00 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 26.40 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | -51.94 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 593.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 8.08 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 53.62 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 42.73 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 329.00 Mn |
| Mar 31, 2026 | 348.40 Mn |
| Dec 31, 2025 | 619.30 Mn |
| Sep 30, 2025 | 658.10 Mn |
| Jun 30, 2025 | 166.80 Mn |
| Mar 31, 2025 | 492.90 Mn |
| Dec 31, 2024 | 342.30 Mn |
| Sep 30, 2024 | 749.50 Mn |
| Jun 30, 2024 | 320.30 Mn |
| Mar 31, 2024 | 564.80 Mn |
| Dec 31, 2023 | 403.00 Mn |
| Sep 30, 2023 | 739.30 Mn |
| Jun 30, 2023 | 457.30 Mn |
| Mar 31, 2023 | 923.40 Mn |
| Dec 31, 2022 | 35.30 Mn |
| Sep 30, 2022 | 765.10 Mn |
| Jun 30, 2022 | 718.60 Mn |
| Mar 31, 2022 | 1.07 Bn |
| Dec 31, 2021 | 325.70 Mn |
| Sep 30, 2021 | 964.60 Mn |